WO2022037544A1 - 一种托伐普坦的药物固体制剂及制备方法 - Google Patents

一种托伐普坦的药物固体制剂及制备方法 Download PDF

Info

Publication number
WO2022037544A1
WO2022037544A1 PCT/CN2021/112856 CN2021112856W WO2022037544A1 WO 2022037544 A1 WO2022037544 A1 WO 2022037544A1 CN 2021112856 W CN2021112856 W CN 2021112856W WO 2022037544 A1 WO2022037544 A1 WO 2022037544A1
Authority
WO
WIPO (PCT)
Prior art keywords
tolvaptan
solid preparation
pharmaceutical
preparation
spray
Prior art date
Application number
PCT/CN2021/112856
Other languages
English (en)
French (fr)
Inventor
赵小洁
王立
候立新
徐霞
张涛
刘玉兰
Original Assignee
福安药业集团重庆礼邦药物开发有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 福安药业集团重庆礼邦药物开发有限公司 filed Critical 福安药业集团重庆礼邦药物开发有限公司
Publication of WO2022037544A1 publication Critical patent/WO2022037544A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis

Definitions

  • the invention belongs to the field of pharmaceutical preparations, and relates to a solid pharmaceutical preparation of tolvaptan and a preparation method thereof.
  • Tolvaptan was developed by Japan's Otsuka Pharmaceutical Company and was launched in the United States and Europe in 2009 under the trade name: SAMSCA.
  • Chemical name of tolvaptan N-[4-[(5R)-7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-formyl]- 3-methylphenyl]-2-methylbenzamide, its structural formula is as follows:
  • Tolvaptan is a selective V2 vasopressin receptor antagonist indicated for the treatment of hyponatremia caused by congestive heart failure, cirrhosis, and the syndrome of insufficiency of antidiuretic hormone secretion.
  • Tolvaptan pharmaceutical solid preparations can increase the concentration of sodium ions in the plasma and help to excrete excess water from the urine.
  • Tolvaptan BCS is classified as class IV, insoluble and difficult to absorb drugs, and the drug bioavailability in vivo is low.
  • tolvaptan and hydroxypropyl cellulose are prepared into an amorphous composition by dissolving in organic solvent dichloromethane and methanol and/or ethanol, and then spray-drying, and It is disclosed that the amount of hydroxypropyl cellulose is 0.2-1 times that of tolvaptan, but the invention does not specify the particle size control range of the solid dispersion, and the dissolution and absorption of the drug cannot be well controlled. After research, solid dispersions with different particle sizes have obvious effects on drug dissolution and in vivo bioavailability.
  • the authorized patent CN102406622B of Zhejiang Huahai Pharmaceutical Co., Ltd. uses spray drying to process tolvaptan, but does not mention particle size control.
  • the present invention conducts detailed in vitro and in vivo studies on the spray drying process conditions of tolvaptan and the particle size of the solid dispersion.
  • the composition prepared from a solid dispersion with a finer particle size has higher biological activity in vivo.
  • Solid dispersions prepared from tolvaptan require a specific particle size range to ensure good bioavailability of the composition.
  • the optimum particle size range of the solid dispersion is found through the research of solid dispersions with different particle sizes, thereby completing the invention.
  • the purpose of the invention is to spray-dry tolvaptan to obtain tolvaptan solid dispersion, and to find out the optimal particle size control range of the solid dispersion.
  • the solid dispersion is prepared into a pharmaceutical solid preparation containing tolvaptan with good bioavailability.
  • a tolvaptan pharmaceutical solid preparation of the present invention comprising tolvaptan in the form of solid dispersion, is characterized in that the particle size D90 of the tolvaptan solid dispersion is 35-80 microns, and the tolvaptan particle size D90 is 35-80 microns.
  • Solid dispersions are prepared by spray drying.
  • the spray drying comprises mixing tolvaptan and hydroxypropyl cellulose, wherein the weight ratio of tolvaptan and hydroxypropyl cellulose is 1:0.5 -1:1, preferably 1:0.5, dissolved in an organic solvent to form a uniform drug-carrying solution, which is spray-dried, characterized in that the spray-drying process parameter selection air inlet temperature is 90 °C-150 °C, and the air volume is 0.1 -0.5m 3 /h.
  • the technical parameters of the spray drying process are selected as the inlet air temperature at 110°C-140°C and the air volume at 0.3-0.5 m 3 /h.
  • the organic solvent is selected from one or more of 95% ethanol, absolute ethanol, dichloromethane and isopropanol, preferably absolute ethanol or dichloromethane .
  • the above-mentioned tolvaptan pharmaceutical solid preparation of the present invention further comprises pharmaceutical excipients such as filler, binder, disintegrant or/and lubricant.
  • the filler is lactose, corn starch or/and microcrystalline cellulose
  • the binder is hydroxypropyl cellulose
  • the disintegrant is low-substituted hydroxypropyl cellulose
  • the lubricant is self- Magnesium stearate.
  • the above-mentioned tolvaptan pharmaceutical solid preparation of the present invention is a combination of tolvaptan solid dispersion granules and pharmaceutical excipients such as fillers selected from lactose, cornstarch or/and microcrystalline cellulose, adhesive hydroxypropyl cellulose.
  • pharmaceutical excipients such as fillers selected from lactose, cornstarch or/and microcrystalline cellulose, adhesive hydroxypropyl cellulose.
  • Gluten, low-substituted hydroxypropyl cellulose as a disintegrant, and magnesium stearate as a lubricant are mixed and granulated to obtain granules or further compressed into tablets.
  • the tolvaptan pharmaceutical solid preparation of the present invention is realized according to the following scheme, and its technical scheme includes:
  • Tolvaptan amorphous solid dispersion is obtained by spray drying: the method includes the following steps:
  • the mixture in the step (1) is completely dissolved in one or more organic solvents in 95% ethanol, dehydrated alcohol, dichloromethane, and isopropanol to obtain a drug-carrying solution; more preferably dehydrated alcohol and dichloromethane two organic solvents;
  • step (3) subjecting the drug-carrying solution in step (2) to spray drying, controlling the drying temperature at 90°C-150°C, spray pressure at 0.01-0.1MPa, liquid feeding speed at 20-25rpm, and air volume at 0.1-0.5m 3 /h, Tolvaptan solid dispersion powder is obtained; by adjusting the spray drying process parameters, solid dispersions of different particle sizes with D90 between 10-120 microns are obtained.
  • the particle size measuring instrument is Malvern 3000, and the measuring method is dry method.
  • step (1) (2) adding low-substituted hydroxypropyl cellulose and magnesium stearate to the tolvaptan intermediate granules in step (1), mixing and compressing to obtain a pharmaceutical solid preparation comprising tolvaptan, namely a tablet .
  • the tolvaptan pharmaceutical solid preparations such as tablets of the present invention have very good and high bioavailability.
  • Fig. 1 is the dissolution curve of the tablet of comparative example and embodiment 1-5 and comparative example in pH1.2 hydrochloric acid medium;
  • Figure 2 is the dissolution curve of the tablets of Examples 1-5 in 0.1N hydrochloric acid (containing 0.05% SDS) medium;
  • FIG. 3 is the human pharmacokinetic plasma concentration curve of the tablets of Examples 1, 3 and 5.
  • FIG. 3 is the human pharmacokinetic plasma concentration curve of the tablets of Examples 1, 3 and 5.
  • Preparation method Weigh microcrystalline cellulose, corn starch, lactose and tolvaptan solid dispersion powder, pass through a 60 mesh sieve and disperse; add a binder solution prepared from hydroxypropyl cellulose, and perform one-step fluidized bed granulation , drying; and then adding low-substituted hydroxypropyl cellulose and magnesium stearate for tableting to obtain a pharmaceutical solid preparation comprising tolvaptan.
  • the spray-dried amorphous powder obtained by the above process is used, and the tolvaptan pharmaceutical solid preparation is prepared by a fluidized bed process to obtain tolvaptan tablets.
  • the granulation recipe process is the same as that in Example 1.
  • the spray-dried amorphous powder obtained by the above process is used, and the tolvaptan pharmaceutical solid preparation is prepared by a fluidized bed process to obtain tolvaptan tablets.
  • the granulation recipe process is the same as that in Example 1.
  • the spray-dried amorphous powder obtained by the above process is used, and the tolvaptan pharmaceutical solid preparation is prepared by a fluidized bed process to obtain tolvaptan tablets.
  • the granulation recipe process is the same as that in Example 1.
  • the spray-dried amorphous powder obtained by the above process is used, and the tolvaptan pharmaceutical solid preparation is prepared by a fluidized bed process to obtain tolvaptan tablets.
  • the granulation recipe process is the same as that in Example 1.
  • Preparation method directly weigh tolvaptan raw materials and auxiliary materials, pass through a 60-mesh sieve to disperse, mix in a mixer for 10-30 minutes, carry out dry granulation, and then add magnesium stearate to mix and compress to obtain a mixture containing tolvaptan.
  • the pharmaceutical solid preparation of Putan is shown in Table 2 below.
  • Example 6 Dissolution curve under the condition of PH1.2 hydrochloric acid
  • Example 1 the dissolution rate and cumulative dissolution amount are significantly higher than other examples; when D90 is 39-77 microns (Examples 2-4), the dissolution rate and cumulative dissolution amount are basically the same, lower than Example 1; when D90 was 104 microns (Example 5), the dissolution rate and cumulative dissolution amount were significantly lower than those of other examples. Among them, the dissolution of the comparative example is significantly lower than that of the example.
  • Example 7 Dissolution profile under 0.1N hydrochloric acid
  • Example 1 In 0.1N hydrochloric acid (containing 0.05% SDS) medium, paddle method 50rpm, 900ml volume medium conditions, the dissolution of the tablets of Example 1-Example 5 was measured. The results are shown in Table 4 below and Figure 2 in the description.
  • Example 1 Example 1 and Example 5 were selected respectively to carry out the human pharmacokinetic experiment.
  • the results are shown in Tables 5-7 and accompanying drawing 3 of the description.
  • Example 1 when the particle size of the solid dispersion is 56 microns, the plasma concentration is the highest, and the bioavailability in vivo is the highest; when the particle size of the solid dispersion is about 21 microns and 104 microns , the blood concentration is low. It can be seen that although the in vitro dissolution of Example 1 is the highest, its in vivo results Cmax and AUC are not ideal, which are significantly lower than those of Example 3. Example 5 had the lowest results in both in vivo and in vitro assays.
  • the tolvaptan combined solid dispersion is preferred.
  • a suitable particle size range is 35-80 microns.

Abstract

一种包含托伐普坦的药物固体制剂及制备方法：将托伐普坦原料药通过喷雾干燥处理，转化为无定形；其特征在于控制无定形固体分散体粉末粒径D90在35-80微米；加入乳糖、玉米淀粉、微晶纤维素、羟丙纤维素、低取代羟丙纤维素、硬脂酸镁等辅料，通过流化床制粒，得到托伐普坦药物固体制剂。

Description

一种托伐普坦的药物固体制剂及制备方法 技术领域
本发明属于药物制剂领域，涉及一种托伐普坦的药物固体制剂及其制备方法。
背景技术
托伐普坦由日本大冢制药公司开发，2009年分别在美国和欧洲上市，商品名：SAMSCA。托伐普坦化学名：N-[4-[(5R)-7-氯-5-羟基-2，3，4，5-四氢-1-苯并氮杂卓-1-甲酰基]-3-甲基苯基]-2-甲基苯甲酰胺，其结构式如下：
Figure PCTCN2021112856-appb-000001
托伐普坦是选择性V2加压素受体拮抗剂，可用来治疗由充血性心衰、肝硬化以及抗利尿激素分泌不足综合征导致的低钠血症。托伐普坦药物固体制剂可以升高血浆中钠离子浓度，帮助多余的水分从尿液排出。
托伐普坦BCS分类为Ⅳ类、难溶解难吸收药物，在体内药物生物利用度较低。
大冢制药的公开专利CN101686941A中公开了托伐普坦原料药和羟丙基纤维素通过溶于有机溶剂二氯甲烷与甲醇和/或乙醇，然后通过喷雾干燥方式制备成非晶形组合物，且公开了羟丙基纤维素量为托伐普坦的0.2-1倍，但该发明未说明固体分散体的粒径控制范围，无法很好的控制药物的溶解吸收。经研究，不同粒径固体分散体对药物的溶解和体内生物利用度有明显影响。
中国专利CN107963991A中为提高溶解性，将托伐普坦溶解重新析出，然后冷冻干燥得到无定型物；所用有机溶剂种类多，不利于绿色化学理念；且该技术不好控制无定型物粒径。
浙江华海药业股份有限公司的授权专利CN102406622B中采用喷雾干燥方式 处理托伐普坦，但未提及控制粒径。
四川百利药业有限责任公司的授权专利CN102366412B中提到，将托伐普坦喷雾粉末粉碎过筛处理控制粒径，其操作流程较繁琐，粉碎处理过程物料损失较大，存在技术缺陷。
本发明对托伐普坦喷雾干燥工艺条件和固体分散体的粒径进行详细的体内外研究，令人意想不到的是并非粒径更细的固体分散体制备的组合物在体内有更高的生物利用度。托伐普坦制备的固体分散体需要一个特定的粒径范围才能确保组合物有良好的生物利用度。本发明通过不同粒径固体分散体的研究，发现了固体分散体最佳的粒径范围，从而完成发明。
发明内容
本发明目的在于对托伐普坦进行喷雾干燥处理，得到托伐普坦固体分散体，找出固体分散体的最佳粒度控制范围。并将固体分散体制备成一种生物利用度好的包含托伐普坦的药物固体制剂。
具体地，旨在实现上述目的，提供如下技术方案：
本发明的一种托伐普坦药物固体制剂，包含固体分散体形式的托伐普坦，其特征在于托伐普坦固体分散体颗粒粒径D90为35-80微米，所述托伐普坦固体分散体是通过喷雾干燥制得的。
上述本发明的托伐普坦药物固体制剂，所述喷雾干燥，包括将托伐普坦与羟丙基纤维素混合，其中，托伐普坦与羟丙基纤维素的重量比为1:0.5-1:1，优选为1:0.5，溶于有机溶剂中，形成均匀的载药溶液，经过喷雾干燥处理，其特征在于喷雾干燥过程工艺参数选择进风温度在90℃-150℃，风量0.1-0.5m 3/h。优选的，所述喷雾干燥过程工艺参数选择进风温度在110℃-140℃，风量0.3-0.5m 3/h。
上述本发明的托伐普坦药物固体制剂，所述有机溶剂选自95％乙醇、无水乙醇、二氯甲烷和异丙醇中的一种或多种，优选为无水乙醇或二氯甲烷。
上述本发明的托伐普坦药物固体制剂，还包含药用辅料如填充剂、粘合剂、崩解剂或/和润滑剂。优选的，所述填充剂为乳糖、玉米淀粉或/和微晶纤维素；所述粘合剂为羟丙纤维素；所述崩解剂为低取代羟丙纤维素；所述润滑剂为自硬脂酸镁。
上述本发明的托伐普坦药物固体制剂，是将托伐普坦固体分散体颗粒与药用辅料如选自乳糖、玉米淀粉或/和微晶纤维素的填充剂、粘合剂羟丙纤维素、崩解剂低取代羟丙纤维素、润滑剂硬脂酸镁进行混合制粒，得到颗粒或进一步压制成片。
在一具体实施方案中，本发明的托伐普坦药物固体制剂按以下方案实现，其技术方案包括：
1、通过喷雾干燥处理得到托伐普坦无定型固体分散体：方法包括以下步骤：
(1)将1:0.5-1:1的托伐普坦和羟丙基纤维素混合；更优选1:0.5的托伐普坦和羟丙基纤维素混合；
(2)将步骤(1)中的混合物完全溶解到95％乙醇、无水乙醇、二氯甲烷、异丙醇中的一种或几种有机溶剂中，得到载药溶液；更优选无水乙醇和二氯甲烷两种有机溶剂；
(3)将步骤(2)中的载药溶液经过喷雾干燥处理，控制干燥温度90℃-150℃，喷雾压力0.01-0.1MPa，送液速度20-25rpm，风量0.1-0.5m 3/h，得到托伐普坦固体分散体粉末；通过调节喷雾干燥工艺参数，得到D90在10-120微米之间的不同粒径固体分散体。粒度测定仪器为马尔文3000，测定方法为干法测定。
2、将1方案得到的托伐普坦固体分散体，制成托伐普坦药物固体制剂，方法包括以下步骤：
(1)将1方案得到的固体分散体粉末，加入玉米淀粉、乳糖或微晶纤维素，与羟丙纤维素混合，通过流化床制粒，得到包含托伐普坦的中间体颗粒；
(2)将步骤(1)中的托伐普坦中间体颗粒，加入低取代羟丙基纤维素、硬脂酸镁，混合压片，得到包含托伐普坦的药物固体制剂，即片剂。
3、对2方案制备的不同粒径固体分散体的片剂测定体外溶出和药代动力学试验，从而完成本发明。
本发明的托伐普坦药物固体制剂如片剂具有非常好和高的生物利用度。
附图说明：
图1为对比例与实施例1-5及对比例的片剂在pH1.2盐酸介质中的溶出曲线；
图2为实施例1-5的片剂在0.1N盐酸(含0.05％SDS)介质中溶出曲线；
图3为实施例1、3、5的片剂的人体药代动力血药浓度曲线。
具体实施方式
以下实施例用于进一步说明和理解本发明的精神实质，但不此限制本发明的范围，任何在本发明的精神实质下进行的简单变通或修饰都属于本发明的范围。
实施例1 托伐普坦固体制剂片剂的制备
将1:0.5的托伐普坦和羟丙基纤维素混合后加入无水乙醇和二氯甲烷中完全溶解，进行喷雾干燥，调整进风温度在130度，喷雾压力为0.06MPa，送液速度20rpm，风量0.3m 3/h，得到固体分散体无定型粉末，测定其粒径D90为21微米。
采用上述过程所得喷雾干燥无定型粉末，通过流化床工艺进行托伐普坦药物固体制剂制备，得到托伐普坦片剂，处方如下：
表1 实施例处方
Figure PCTCN2021112856-appb-000002
制备方法：称取微晶纤维素、玉米淀粉、乳糖和托伐普坦固体分散体粉末，过60目筛分散；加入羟丙纤维素配制成的粘合剂溶液，进行流化床一步制粒、干燥；然后加入低取代羟丙纤维素和硬脂酸镁压片，得到包含托伐普坦的药物固体制剂。
实施例2 托伐普坦固体制剂片剂的制备
将1:0.5的托伐普坦和羟丙基纤维素混合后加入无水乙醇和二氯甲烷中完全溶解，进行喷雾干燥；调整进风温度在130度，喷雾压力为0.045MPa，送液速度25rpm，风量0.3m 3/h，得到固体分散体无定型粉末，测定其粒径D90为39 微米。
采用上述过程所得喷雾干燥无定型粉末，通过流化床工艺进行托伐普坦药物固体制剂制备，得到托伐普坦片剂。制粒处方工艺同实施例1。
实施例3 托伐普坦固体制剂片剂的制备
将1:0.5的托伐普坦和羟丙基纤维素混合后加入无水乙醇和二氯甲烷中完全溶解，进行喷雾干燥；调整进风温度在130度，喷雾压力为0.03MPa，送液速度25rpm，风量0.3m 3/h，得到固体分散体无定型粉末，测定其粒径D90为56微米。
采用上述过程所得喷雾干燥无定型粉末，通过流化床工艺进行托伐普坦药物固体制剂制备，得到托伐普坦片剂。制粒处方工艺同实施例1。
实施例4 托伐普坦固体制剂片剂的制备
将1:0.5的托伐普坦和羟丙基纤维素混合后加入无水乙醇和二氯甲烷中完全溶解，进行喷雾干燥；调整进风温度在110度，喷雾压力为0.03MPa，送液速度23-24rpm，风量0.3m 3/h，得到固体分散体无定型粉末，测定其粒径D90为77微米。
采用上述过程所得喷雾干燥无定型粉末，通过流化床工艺进行托伐普坦药物固体制剂制备，得到托伐普坦片剂。制粒处方工艺同实施例1。
实施例5 托伐普坦固体制剂片剂的制备
将1:0.5的托伐普坦和羟丙基纤维素混合后加入无水乙醇和二氯甲烷中完全溶解，进行喷雾干燥；调整进风温度在145度，喷雾压力为0.03MPa，送液速度25rpm，风量0.3m 3/h，得到固体分散体无定型粉末，测定其粒径D90为104微米。
采用上述过程所得喷雾干燥无定型粉末，通过流化床工艺进行托伐普坦药物固体制剂制备，得到托伐普坦片剂。制粒处方工艺同实施例1。
对比例：干法制粒工艺
制备方法：直接称取托伐普坦原料药和辅料，过60目筛分散，于混合机中混合10-30分钟，进行干法制粒，然后加入硬脂酸镁混合压片，得到包含托伐普坦的药物固体制剂。对比例的处方见下表2。
表2 对比例的处方
Figure PCTCN2021112856-appb-000003
实施例6：PH1.2盐酸条件下的溶出曲线
测定实施例1-实施例5和对比例制备的托伐普坦片的溶出曲线。溶出条件：PH1.2盐酸，桨法50rpm，介质体积900ml，结果见如下表3和说明书附图1。
表3 实施例片剂及对比例片剂溶出实验结果
Figure PCTCN2021112856-appb-000004
以上数据表明，在溶出介质不加入表面活性剂的情况下，随固体分散体粒径增加，溶出有降低趋势。D90为21微米时(实施例1)，溶出速度和累积溶出量明显高出其他实施例；D90为39～77微米时(实施例2～4)，溶出速度和累积溶出量基本相当，低于实施例1；D90为104微米时(实施例5)，溶出速度和累积溶出量明显低于其他实施例。其中对比例溶出明显低于实施例。
实施例7：0.1N盐酸下的溶出曲线
在0.1N盐酸(含0.05％SDS)介质，桨法50rpm，900ml体积介质条件，测定实施例1-实施例5片剂的溶出，结果见如下表4和说明书附图2。
表4 实施例1-5的片剂的溶出实验结果
Figure PCTCN2021112856-appb-000005
在以上介质条件下，不同粒径固体分散体实施例溶出整体差异不明显。
分别选用以上实施例1、实施例3、实施例5样品，进行人体药代动力学实验，结果如下表5-表7和说明书附图3。
表5 实施例1人体药代动力学实验结果
Figure PCTCN2021112856-appb-000006
表6 实施例3人体药代动力学实验结果
Figure PCTCN2021112856-appb-000007
表7 实施例5人体药代动力学实验结果
Figure PCTCN2021112856-appb-000008
根据以上人体药代动力学结果(见说明书附图3)，固体分散体粒径在56微米时，血药浓度最高，体内生物利用度最高；固体分散体粒径在21微米和104微米左右时，血药浓度较低。由此可见，虽然实施例1的体外溶出最高，但其在体内的结果Cmax和AUC并非最理想，明显低于实施例3。实施例5的体内和体外测定结果均最低。可见，当托伐普坦固体分散体粒径过细或过粗时，体内生物利用度都较低，粒径适中时，生物利用度较高，结合溶出结果，优选托伐普坦合固体分散体合适粒径范围为35-80微米。

Claims (10)

  1. 一种托伐普坦的药物固体制剂，包含固体分散体形式的托伐普坦，其特征在于托伐普坦固体分散体颗粒粒径D90为35-80微米。
  2. 如权利要求1所述的药物固体制剂，所述托伐普坦固体分散体是通过喷雾干燥制得的。
  3. 如权利要求2所述的药物固体制剂，所述喷雾干燥，包括将托伐普坦与羟丙基纤维素混合，溶于有机溶剂中，形成载药溶液，经过喷雾干燥处理，其特征在于喷雾干燥过程工艺参数选择进风温度在90℃-150℃，风量0.1-0.5m 3/h。
  4. 如权利要求3所述的药物固体制剂，所述喷雾干燥过程工艺参数选择进风温度在110℃-140℃，风量0.3-0.5m 3/h。
  5. 如权利要求4所述的药物固体制剂，托伐普坦与羟丙基纤维素的重量比为1:0.5-1:1。
  6. 如权利要求5所述的药物固体制剂，托伐普坦与羟丙基纤维素的重量比为1:0.5。
  7. 如权利要求3所述的药物固体制剂，所述有机溶剂选自95％乙醇、无水乙醇、二氯甲烷和异丙醇中的一种或多种，优选为无水乙醇或二氯甲烷。
  8. 如权利要求1所述的药物固体制剂，还包含药用辅料填充剂、粘合剂、崩解剂或/和润滑剂。
  9. 权利要求8所述的药物固体制剂，所述填充剂为乳糖、玉米淀粉或/和微晶纤维素；所述粘合剂为羟丙纤维素；所述崩解剂为低取代羟丙纤维素；所述润滑剂为自硬脂酸镁。
  10. 如权利要求9所述的药物固体制剂，是将托伐普坦固体分散体颗粒与药用辅料进行制粒，得到颗粒或进一步压制成片。
PCT/CN2021/112856 2020-08-21 2021-08-16 一种托伐普坦的药物固体制剂及制备方法 WO2022037544A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010848996.7A CN111888335A (zh) 2020-08-21 2020-08-21 一种托伐普坦的药物固体制剂及制备方法
CN202010848996.7 2020-08-21

Publications (1)

Publication Number Publication Date
WO2022037544A1 true WO2022037544A1 (zh) 2022-02-24

Family

ID=73229810

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/112856 WO2022037544A1 (zh) 2020-08-21 2021-08-16 一种托伐普坦的药物固体制剂及制备方法

Country Status (2)

Country Link
CN (1) CN111888335A (zh)
WO (1) WO2022037544A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024030098A1 (en) * 2022-08-03 2024-02-08 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A tablet of tolvaptan and at least one binder processed with spray granulation

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111888335A (zh) * 2020-08-21 2020-11-06 福安药业集团重庆礼邦药物开发有限公司 一种托伐普坦的药物固体制剂及制备方法
CN113171344B (zh) * 2021-04-12 2023-01-31 南京海纳医药科技股份有限公司 一种托伐普坦口服制剂及其制备方法
WO2023128905A1 (en) * 2021-12-30 2023-07-06 Santa Farma Ilac Sanayii A.S. Pharmaceutical composition comprising amorphous tolvaptan

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102293734A (zh) * 2010-06-25 2011-12-28 江苏恒瑞医药股份有限公司 托伐普坦固体分散体及其制备方法
CN102366412A (zh) * 2011-10-21 2012-03-07 四川百利药业有限责任公司 一种托伐普坦片剂的制备方法
CN103463095A (zh) * 2007-06-21 2013-12-25 大塚制药株式会社 包含苯并氮杂*的药物固体制剂及其生产方法
CN105007897A (zh) * 2013-03-01 2015-10-28 大塚制药株式会社 含有无定形托伐普坦的口服施用的混悬剂
CN111888335A (zh) * 2020-08-21 2020-11-06 福安药业集团重庆礼邦药物开发有限公司 一种托伐普坦的药物固体制剂及制备方法
CN113171344A (zh) * 2021-04-12 2021-07-27 南京海纳医药科技股份有限公司 一种托伐普坦口服制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4210355B2 (ja) * 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
TW201010743A (en) * 2008-09-05 2010-03-16 Otsuka Pharma Co Ltd Pharmaceutical solid preparation
CN103007286B (zh) * 2011-09-28 2016-06-15 北京本草天源药物研究院 一种托伐普坦的固体药物组合物
CN102406622B (zh) * 2011-11-16 2017-02-08 浙江华海药业股份有限公司 一种托伐普坦的固体制剂
CN102512393A (zh) * 2011-12-19 2012-06-27 浙江华海药业股份有限公司 一种托伐普坦的口腔崩解片
JP2018024628A (ja) * 2016-08-02 2018-02-15 ニプロ株式会社 トルバプタンを含む非晶質固体分散体およびその製造方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103463095A (zh) * 2007-06-21 2013-12-25 大塚制药株式会社 包含苯并氮杂*的药物固体制剂及其生产方法
CN102293734A (zh) * 2010-06-25 2011-12-28 江苏恒瑞医药股份有限公司 托伐普坦固体分散体及其制备方法
CN102366412A (zh) * 2011-10-21 2012-03-07 四川百利药业有限责任公司 一种托伐普坦片剂的制备方法
CN105007897A (zh) * 2013-03-01 2015-10-28 大塚制药株式会社 含有无定形托伐普坦的口服施用的混悬剂
CN111888335A (zh) * 2020-08-21 2020-11-06 福安药业集团重庆礼邦药物开发有限公司 一种托伐普坦的药物固体制剂及制备方法
CN113171344A (zh) * 2021-04-12 2021-07-27 南京海纳医药科技股份有限公司 一种托伐普坦口服制剂及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024030098A1 (en) * 2022-08-03 2024-02-08 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A tablet of tolvaptan and at least one binder processed with spray granulation

Also Published As

Publication number Publication date
CN111888335A (zh) 2020-11-06

Similar Documents

Publication Publication Date Title
WO2022037544A1 (zh) 一种托伐普坦的药物固体制剂及制备方法
CN108472261B (zh) 阿哌沙班固体组合物及其制备方法
WO2019214512A1 (zh) 维生素d类似物制剂及其制备方法
WO2017170858A1 (ja) 溶出性に優れた経口製剤
WO2022012172A1 (zh) 一种难溶性药物口服缓释组合物及其制备方法
TR201620462A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
CN109528675A (zh) 一种他达拉非肠溶片剂及其制备方法
CN110354086B (zh) 一种坎地沙坦酯片剂的制备方法
CN113041250B (zh) 一种缬沙坦氢氯噻嗪复方制剂及其制备工艺
CN105434386A (zh) 一种含有高水溶性活性成分的缓释片剂及其制备方法
CN108078934A (zh) 一种盐酸齐拉西酮固体分散片及其热熔挤出方法
WO2021042278A1 (zh) 一种阿昔莫司多单元缓释微丸片及其制备方法
CN110123770A (zh) 一种阿哌沙班药物组合物及其制备方法
CN115463097B (zh) 一种他克莫司缓释中间体颗粒的制备工艺
CN106539769A (zh) 一种鲁拉西酮片及其制备方法
CN112516101B (zh) 一种含有富马酸喹硫平的片剂及其制备方法
CN112641743B (zh) 一种用于治疗高血压的复方制剂及其制备工艺
JP5669751B2 (ja) 低い経口生物学的利用能を有する化合物のプレ圧縮崩壊性製剤
CN115919793A (zh) 一种奥利司他胶囊制剂及其制备方法
WO2022062096A1 (zh) 一种改善羟乙磺酸哌柏西利流动性的工艺方法及组合物
CN113456601A (zh) 一种坎地沙坦酯氢氯噻嗪复方片剂的制备方法
WO2019101150A1 (zh) 一种海泽麦布片剂及其制备方法
CN106983752B (zh) 一种缬沙坦氢氯噻嗪胶囊的制备方法
CN104027316B (zh) 一种格列美脲片剂及其制备方法
CN117100715A (zh) 一种含无定型尼洛替尼的胶囊及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21857638

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21857638

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 21857638

Country of ref document: EP

Kind code of ref document: A1